Blood Glucose Homeostasis in Type 2 Diabetes: the Effects of Saccharose
1 other identifier
interventional
39
1 country
1
Brief Summary
Hyperglycemia forms a direct and independent risk factor for the development of cardiovascular co-morbidities in type 2 diabetes. Consumption of sucrose-sweetened soft drinks might further increase the prevalence of hyperglycemic episodes. The objective of the study was to assess glycemic control in type 2 diabetes patients and healthy lean and obese controls under strict dietary standardization but otherwise free living conditions, with and without the consumption of soft drinks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable type-2-diabetes
Started Mar 2007
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2008
CompletedFirst Submitted
Initial submission to the registry
January 12, 2009
CompletedFirst Posted
Study publicly available on registry
January 13, 2009
CompletedJanuary 13, 2009
January 1, 2009
1.5 years
January 12, 2009
January 12, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Hyperglycemia
24h
Secondary Outcomes (1)
Hyperglycemia
Postprandially
Study Arms (2)
Sucrose
EXPERIMENTALSucrose
Water
PLACEBO COMPARATORWater
Interventions
Eligibility Criteria
You may qualify if:
- Lean NGT Group
- Normoglycemic (according to 2006 ADA guidelines)
- BMI \< 27 kg/m2
- Obese NGT Group
- Normoglycemic
- BMI 30- 35 kg/m2
- Obese type 2 diabetes Group
- BMI 30- 35 kg/m2
- Oral blood glucose lowering medication
You may not qualify if:
- Exogenous insulin use
- Cardiac disease (any cardiac event in the last 5 years)
- HbA1c \>10%
- Microalbuminuria: albumin:creatinine ratio \>2,5
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Maastricht University
Maastricht, Limbrug, 6200 MD, Netherlands
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Luc J van Loon, Ph.D
Maastricht University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
January 12, 2009
First Posted
January 13, 2009
Study Start
March 1, 2007
Primary Completion
September 1, 2008
Study Completion
September 1, 2008
Last Updated
January 13, 2009
Record last verified: 2009-01